Friend MTS, Leading Global Provider of Content Protection Services, Announces Appointment of Derek Chang to Chief Executive Officer
2.6.2021 14:00:00 EEST | Business Wire | Press release
Friend MTS is pleased to announce the appointment of Derek Chang to Chief Executive Officer (CEO). A seasoned industry executive with a career spanning three decades, Chang previously served as CEO of NBA China, and has held leadership positions with several recognized sports, media and entertainment providers. He will be based in London.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602005316/en/
Derek Chang, Chief Executive Officer, Friend MTS (Photo: Business Wire)
“It is my privilege to join Friend MTS as we ramp up our innovation of the technology essential to protect the needs of a complex global media industry,” said Chang. “We are at the forefront of rapid changes in consumer behavior, new business models and technology, and will ensure that creators, owners and distributors worldwide will have the formidable tools necessary to protect their valuable content.”
The announcement was made today by Jonathan Friend, Founder, Friend MTS, who previously served as CEO. A visionary in the field of content protection technologies, Friend will serve as Chief Product Officer (CPO) and continue to drive growth through the creation of the company’s advanced proprietary solutions.
“As we continue to innovate with groundbreaking solutions that our valued customers and partners have come to expect, now is the time to transition to our next leader and we are thrilled to welcome Derek to the helm of Friend MTS,” said Friend. “With deep expertise in the global sports and entertainment space, Derek brings invaluable insight to leveraging technology to create an impactful footprint for an ever-evolving media and content ecosystem.”
Prior to leading NBA China’s business, Chang was Head of International Lifestyle Channels for Scripps Networks Interactive, and had served as Executive Vice President, Content, DIRECTV. He also held senior roles for Charter Communications, the YES Network and TCI Communications. Chang currently serves on the board of directors for Liberty Media Corp. and Isos Acquisition Corp., and formerly served on the board of Starz.
Chang was named one of the “50 Most Influential People in Sports Business” by Sports Business Journal, as well as Cablefax Magazine's “Top 100 Executives in Cable.” He holds an MBA from Stanford University and a bachelor's degree in history from Yale University. He is a member of the Committee of 100 and serves on the advisory board of Row New York.
For press use, Friend MTS photo assets can be downloaded here. For more information, please visit www.friendmts.com or follow on LinkedIn and Twitter.
About Friend MTS:
Friend MTS is a leading global provider of innovative content protection technology solutions developed to advance a complex and ever-evolving media industry in collaboration with content owners, broadcasters and operators. With a comprehensive suite of advanced proprietary services ranging from content monitoring, fingerprinting and watermarking to enforcement and IP blocking, Friend MTS provides an end-to-end approach to disrupt real-world piracy and safeguard a worldwide entertainment and media market into the future. Playing an important role in social responsibility, Friend MTS has gifted organizations like the U.S. Department of Homeland Security and the International Center for Missing and Exploited Children (ICMEC) with its award-winning technology to help combat online child abuse. Founded in 2000, Friend MTS is privately held and headquartered in Birmingham, U.K. and Philadelphia, Pennsylvania, with operations throughout Europe, Asia, the Middle East, Africa, Latin America and North America.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005316/en/
Contact information
Friend MTS Media Contact:
Nora Ellish
+1 (917) 744-9200
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
